论文部分内容阅读
目的本文探讨四组原发性肝癌(PHC)合并门静脉癌栓(PVTT)术后不同化疗途径和给药方式对患者疗效的影响。方法60例PHC合并PVTT病人随机分成4组,A组行经导管化疗栓塞(TACE)治疗;B组行TACE+门静脉置化疗(PVI),且PVI采用快速推注给药;C组行TACE+PVI,且PVI采用电脑控制的微量泵缓慢灌注给药;D组行肝动脉置管化疗栓塞(HAI)+PVI,且PVI采用电脑控制的缓慢灌注给药。结果A、B、C三组间生存率分别有显著性差别(P<0.05),C组疗效较好;C、D两组间生存率差别无显著意义(P>0.05)。结论PLC合并PVTT患者术后宜采用肝动脉门静脉双途径化疗且门静脉宜用持续灌注化疗,而经肝动脉行TACE或HAL均可。
Objective To investigate the effect of different chemotherapy routes and modes of administration on the curative effect of four groups of primary hepatocellular carcinoma (PHC) combined with portal vein tumor thrombus (PVTT). Methods Sixty patients with PHC combined with PVTT were randomly divided into 4 groups: group A received TACE, group B received TACE + PVI, and PVI was given by bolus injection. Group C received TACE + PVI, And PVI was slowly perfusion controlled by a computer-controlled micropump. Group D received HAI + PVI, and PVI was administered by computer-controlled slow perfusion. Results The survival rates of A, B and C groups were significantly different (P <0.05), while C group had better curative effect. There was no significant difference in survival rate between C and D groups (P> 0.05). Conclusion PLC combined with PVTT patients should adopt dual hepatic artery chemotherapy after portal vein chemotherapy and portal vein should be continuous infusion chemotherapy, while via the hepatic artery TACE or HAL can be.